This company is no longer active
PLx Pharma Winddown (PLXP.Q) Stock Overview
PLx Pharma Winddown Corp. operates as a commercial-stage drug delivery platform technology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PLXP.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
PLx Pharma Winddown Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.70 |
| 52 Week Low | US$0.000001 |
| Beta | 3.41 |
| 1 Month Change | -99.50% |
| 3 Month Change | -99.98% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M
Aug 12Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?
May 10
Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable
Nov 03We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow
Sep 23PLx Pharma: First Commercial Launch Makes It Attractive
Sep 17PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business
Jun 15Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?
Mar 05Shareholder Returns
| PLXP.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.04% | 2.1% |
| 1Y | -100.0% | -4.7% | 18.7% |
Return vs Industry: PLXP.Q underperformed the US Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: PLXP.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| PLXP.Q volatility | |
|---|---|
| PLXP.Q Average Weekly Movement | 54.0% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PLXP.Q's share price has been volatile over the past 3 months.
Volatility Over Time: PLXP.Q's weekly volatility (54%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 18 | Pat Lonergan | plxpharma.com |
PLx Pharma Winddown Corp. operates as a commercial-stage drug delivery platform technology company in the United States. The company’s lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever.
PLx Pharma Winddown Corp. Fundamentals Summary
| PLXP.Q fundamental statistics | |
|---|---|
| Market cap | US$30.00 |
| Earnings (TTM) | -US$27.58m |
| Revenue (TTM) | US$4.54m |
Is PLXP.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLXP.Q income statement (TTM) | |
|---|---|
| Revenue | US$4.54m |
| Cost of Revenue | US$4.34m |
| Gross Profit | US$203.00k |
| Other Expenses | US$27.78m |
| Earnings | -US$27.58m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 4.47% |
| Net Profit Margin | -606.91% |
| Debt/Equity Ratio | 0% |
How did PLXP.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/04 13:14 |
| End of Day Share Price | 2023/09/29 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PLx Pharma Winddown Corp. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hamed Khorsand | BWS Financial Inc. |
| Jason Butler | Citizens JMP Securities, LLC |
| Donald Ellis | Citizens JMP Securities, LLC |